Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join our cardiology colleagues at the ACC Annual Meeting, a premier gathering of cardiovascular professionals from around the world. This dynamic conference brings together leading physicians, researchers, healthcare innovators, and industry experts to explore the latest advances in cardiovascular medicine. Attendees will experience cutting-edge clinical education, groundbreaking research presentations, interactive learning sessions, and exceptional networking opportunities focused on improving patient care and advancing the future of heart health.
Latest in Cardiology from ACC.org
- CKD Studies Spotlight GFR Measurement, Finerenone Benefit and Rivaroxaban RiskResearch presented at the European Renal Association Congress, held June 3-6 in Glasgow, Scotland, highlighted new findings in chronic kidney disease (CKD), including evidence supporting more precise GFR assessment and trial results on finerenone in nondiabetic CKD and rivaroxaban in advanced CKD patients with CV risk factors.
- Follow-Up of FAVOR III Suggests QFR-Guided PCI Improves 5-Year OutcomesWhen compared with angiography guidance, quantitative flow ratio (QFR)-guided PCI improved five-year clinical outcomes with benefits primarily achieved in the first two years, according to a follow-up study of the multicenter, sham-controlled FAVOR III trial published June 10 in JACC.
- Follow-Up of CENTRAL, DIRECT-PLUS Suggests Visceral Fat Reduction Has Lasting Metabolic Health BenefitsA long-term follow-up of the CENTRAL and DIRECT-PLUS trials published in Circulation suggests that despite long-term weight regain, visceral fat reduction during lifestyle intervention is associated with sustained improvements in metabolic health.
- SOGALDI-PEF: Baseline Renin Levels Predict BP Treatment EffectPatients with low plasma renin levels had a more pronounced blood pressure (BP) reduction with spironolactone/dapagliflozin vs. dapagliflozin alone, in addition to seeing a more favorable impact on cardiovascular structure and function, while aldosterone levels exhibited no predictive value in treatment response...
- Eagle’s Eye View: Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKDIn this week’s View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care.